Lenacapavir

Molecular mass: 968.28 g/mol 

Therapeutic indications

Lenacapavir is indicated for:

Multidrug resistant HIV-1 infection

Population group: only adults (18 - 65 years old)

Lenacapavir tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, for oral loading prior to administration of long-acting lenacapavir injection

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lenacapavir is contraindicated in the following cases:

CYP3A strong inducers, P-gp strong inducers, UGT1A1 strong inducers

at least one of
Strong potency CYP3A4 inducers
Cytochrome P-450 CYP3A5 strong inducers
P-glycoprotein inducers
Inducers of UGT1A1

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: SUNLENCA Solution for injection
Summary of Product Characteristics (SPC) 2022: SUNLENCA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈